Last reviewed · How we verify
NCT06963840: Ova-All Care
Effect of Theronomic Ova-All Care on Biomarkers of Ovarian Health in Adult Female With Polycystic Ovarian Syndrome
Phase 2 trial testing Theronomic Ova-All Care in Polycystic Ovarian Syndrome (PCOS) in 16 participants. Participants enrolled and being followed up; not accepting new ones.
1 August 2025
Quick facts
| Lead sponsor | Wellizen Australia |
|---|---|
| Phase | Phase 2 |
| Status | Active, enrolled |
| Study type | INTERVENTIONAL |
| Allocation | na |
| Design | single group |
| Masking | none |
| Primary purpose | treatment |
| Enrollment | 16 |
| Start date | 9 May 2025 |
| Primary completion | 1 August 2025 |
| Estimated completion | 1 August 2025 |
| Sites | 1 location across China |
Drugs / interventions tested
- Theronomic Ova-All Care
Conditions studied
- Polycystic Ovarian Syndrome (PCOS) — all drugs for Polycystic Ovarian Syndrome (PCOS) →
Sponsor
Wellizen Australia
Who can join
Adults 18 to 40, female only, with Polycystic Ovarian Syndrome (PCOS). Patients with the condition only — healthy volunteers not accepted.
What's being measured
Primary outcomes are the specific endpoints the trial is designed to prove or disprove.
-
Serum oestrogen level
Time frame: From enrollment to end-of intervention (Week 12)
Serum oestrogen levels determined by blood test, pg/mL We will conduct two subgroup analyses with participants with excessively low (less than 25 pg/mL) and excessively high (more than 138 pg/mL) serum oestrogen levels
Sponsor's own description
Theronomic Ova-All Care is a tribiotic health product aimed at improving ovarian health in people with polycystic ovarian syndrome (PCOS). In this study, a total of 16 participants with PCOS diagnosed by a gynaecologist will be invited to take Ova-All Care, two capsule once a day, for 12 weeks. Biomarkers of ovarian health will be measured at baseline, four weeks after the start of the intervention, and at the end of the intervention.
Publications & conference data
No peer-reviewed publications indexed yet for this trial.
Verify or expand the search:
- PubMed search for NCT06963840
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other recruiting trials for Polycystic Ovarian Syndrome (PCOS)
Currently open trials in the same condition.
- NCT07392476 — Continuous Glucose Monitoring in Polycystic Ovarian Syndrome · active not recruiting
- NCT07157371 — Effects of Aerobic Exercise Training Program in Females With Insulin Resistant Polycystic Ovarian Syndrome · NA · active not recruiting
- NCT07399535 — Clinical Investigation of Herbal Formulation and Its Efficacy in Polycystic Ovarian Syndrome · Phase 1 · recruiting
Other Wellizen Australia trials
Trials by the same sponsor.
- NCT06897462 — Effect of Science Research Wellness Ndo1 on Glycaemia in Adults With Pre-diabetes · NA · completed
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT06963840 (US National Library of Medicine, public domain)
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Wellizen Australia
- Last refreshed: 22 August 2025
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT06963840.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing